Green light to vaccine against respiratory syncytial virus in babies

Green light to vaccine against respiratory syncytial virus in babies

The United States Food and Drug Administration (FDA, in English) gave the green light yesterday to the use of the first vaccine to prevent respiratory syncytial virus (RSV) in infants that is administered to pregnant women.

The drug, marketed under the name Abrysvo and manufactured by Pfizer, was also endorsed by the European Medicines Agency (EMA) in July.

With its approval, the FDA hopes to “provide a choice for healthcare workers and pregnant individuals to protect infants from this potentially fatal disease,” the regulator said in a statement.

The agency considered that the safety and effectiveness of the vaccine have been demonstrated in a series of international clinical studies.in which a significant reduction in the risk of severe RSV cases was detected in infants up to six months of age.

In May, the FDA approved the use of the drug for people 60 and older. In order for the vaccine to begin to be administered to women in the country, the Centers for Disease Control and Prevention (CDC) must first issue a recommendation, according to The Hill.

According to the FDA, RSV is the leading cause of lower respiratory tract infections in infants in the world. The virus usually begins to circulate in autumn and reaches its peak in winter. Although in many cases it only causes symptoms similar to those of a cold, it sometimes causes complications and can lead to bronchitis or pneumonia. It is especially dangerous during the first year of life.

According to the FDA, the main symptoms of Abrysvo in pregnant women are pain at the injection site, muscle pain, nausea, and headache.

Kumneger Media
Kumneger Media
Kumneger Media is a News and Entertainment Website & Channel. Kumneger Media in addition to News and Entertainment it is the hub of Politics, Movies, Drama, Music, Comedy, Documentary and More!